Searchable abstracts of presentations at key conferences in endocrinology

ea0089c43 | Clinical – Surgery/Applied Pathology | NANETS2022

Post-Operative Biochemical Surveillance Thresholds Can be Used to Monitor for Sympathetic Pheochromocytoma/Paraganglioma Recurrence and Metastasis

S Lui Michael , B Fisher Sarah , G Grubbs Elizabeth , D Perrier Nancy , G Waguespack Steven , Varghese Jeena , A Habra Mouhammed , Jimenez Camilo , H Graham Paul

Background: Sympathetic pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors associated with excess catecholamine production. Routine biochemical and imaging surveillance to monitor for recurrence and metastasis is recommended. However, there is limited data describing optimal surveillance approaches and post-operative biochemical thresholds for detecting recurrences or metastases. This study sought to correlate biochemical and imaging surveillance with ...

ea0089t5 | Trials In Progress | NANETS2022

A Phase 2 Open-Label Study of Belzutifan (a HIF-2α Inhibitor) Monotherapy in Patients with Advanced/Metastatic Pheochromocytoma/Paraganglioma or Pancreatic Neuroendocrine Tumors

Jimenez Camilo , Hadoux Julien , Del Rivero Jaydira , Das Satya , Iliopoulos Othon , Sultanbaev Alexander , Artamonova Elena , Jonasch Eric , Pacak Karel , Wang Wei , Jin Fan , S. Naik Girish , Capdevila Jaume

Background: Patients with advanced pheochromocytoma/paraganglioma (PPGL) or pancreatic neuroendocrine tumor (panNET) are in need of novel targeted therapies. Hypoxia-inducible factor 2α (HIF-2α) is one of the key oncogenic drivers in neuroendocrine tumors. Hypoxia signaling pathway alterations or other mechanisms that stabilize HIFs are common in some PPGLs and panNETs. Belzutifan (MK-6482), a HIF-2α inhibitor, has shown antitumor activity in advanced renal cell...